Psilocybin-Assisted Therapy for Major Depressive Disorder: A Clinical Trial

Authors: Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR.

Briefing

This scientific report from JAMA Psychiatry details a randomized clinical trial conducted at Johns Hopkins University to evaluate how psilocybin-assisted therapy affects patients with major depressive disorder.

The study compared a group receiving immediate treatment against a waiting-list control group, discovering that two doses of psilocybin paired with supportive psychotherapy led to large, rapid, and sustained reductions in depressive symptoms.

The researchers emphasize that these therapeutic effects were significantly more robust than those typically seen with standard antidepressants and were associated with personally meaningful or mystical-type experiences during the sessions.

Ultimately, the text highlights the potential for this psychedelic intervention to serve as a breakthrough, transdiagnostic treatment for individuals who may not respond to traditional psychiatric medications.

NotebookLM Interactive Dashboard

Nalaya Retreats is focused on providing our participants and community tools to understand and engage with our tools and services better prepared and fully informed. Our team has curated and prepared with the help of AI an ecosystem to facilitate learning for free.

Find an interactive environment to learn about this study by clicking button, you will be taken to NotebookLM.

Psilocybin-Assisted Therapy for Major Depressive Disorder: A Clinical Trial | Nalaya Retreats NotebookLM

Original Source

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285. Erratum in: JAMA Psychiatry. 2021 Feb 10;78(5):569. doi: 10.1001/jamapsychiatry.2020.4714. PMID: 33146667; PMCID: PMC7643046.